Key Events This Week
21 Sep: Stock opens at Rs.34.10, down 2.60%
22 Sep: Continued decline to Rs.33.86 (-0.70%)
23 Sep: Sharp fall to Rs.32.75 (-3.28%) on high volume
24 Sep: Marginal drop to Rs.32.67 (-0.24%) amid sector weakness
25 Sep: Plunges 20% to hit lower circuit at Rs.26.14, new 52-week low
21 September 2026: Week Begins with Sharp Decline
Medico Remedies Ltd opened the week at Rs.34.10 on 21 September, down 2.60% from the previous close of Rs.35.01. This decline contrasted with the Sensex’s positive gain of 0.46%, closing at 35,787.64. The stock’s volume was moderate at 11,824 shares, signalling early selling pressure. The underperformance set the tone for the week as the stock began a sustained downtrend.
22 September 2026: Continued Downtrend Amid Market Weakness
The downward momentum persisted on 22 September, with the stock slipping further by 0.70% to Rs.33.86. The Sensex also declined by 0.32% to 35,672.04, reflecting a broader market pullback. Trading volume decreased to 7,869 shares, indicating cautious investor participation. The stock remained below key moving averages, reinforcing the bearish technical outlook.
23 September 2026: Significant Drop on Heavy Volume
On 23 September, Medico Remedies Ltd suffered a sharp 3.28% decline to Rs.32.75, accompanied by a surge in volume to 29,537 shares. This day’s drop was in stark contrast to the Sensex’s 0.56% gain, which closed at 35,870.78. The heavy selling pressure suggested growing investor concern, with the stock continuing to trade below all major moving averages, signalling sustained technical weakness.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
24 September 2026: Marginal Decline Amid Sector Weakness
The stock marginally declined by 0.24% to Rs.32.67 on 24 September, with volume at 15,541 shares. The Sensex fell sharply by 1.62% to 35,291.38, reflecting broader market volatility. Despite the slight drop, the stock remained firmly below all key moving averages, continuing its bearish technical stance. Delivery volumes also declined by nearly 49%, indicating reduced conviction among long-term holders.
25 September 2026: Sharp 20% Plunge Hits Lower Circuit
Medico Remedies Ltd’s stock price collapsed by 19.99% on 25 September, closing at Rs.26.14 after hitting the lower circuit limit of ₹26 intraday. This represented a new 52-week low and extended the stock’s losing streak to six consecutive sessions, with a total loss of approximately 28.45% over this period. The day’s trading volume surged to 3,19,711 shares, reflecting intense selling pressure and panic among investors.
The stock’s 20% drop starkly contrasted with the Pharmaceuticals & Biotechnology sector’s negligible decline of 0.01% and the Sensex’s modest gain of 0.18%, underscoring the stock’s acute underperformance. The weighted average price remained close to the lower circuit, indicating a lack of buyer interest at higher levels. Technical indicators remained bearish across all timeframes, with the stock trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages.
Is Medico Remedies Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Weekly Price Performance: Medico Remedies Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.34.10 | -2.60% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.33.86 | -0.70% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.32.75 | -3.28% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.32.67 | -0.24% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.26.14 | -19.99% | 35,353.29 | +0.18% |
Key Takeaways from the Week
Significant Underperformance: Medico Remedies Ltd’s 25.34% weekly decline far exceeded the Sensex’s 0.76% fall, highlighting acute weakness in the stock amid a relatively stable market environment.
Technical Weakness Persists: The stock traded below all major moving averages throughout the week, with bearish signals from MACD, RSI, Bollinger Bands, and other technical indicators, confirming a sustained downtrend.
Heavy Selling Pressure and Lower Circuit: The 20% plunge on 25 September triggered the lower circuit filter, reflecting panic selling and a lack of buyer support at current levels. The high volume on this day underscores the intensity of the sell-off.
Financials Show Growth Despite Price Decline: Despite the sharp price fall, Medico Remedies reported robust net sales growth of 55.32% to Rs.184.89 crores and PAT growth of 28.13% to Rs.11.25 crores for the nine months ended. The company maintains a low Debt to EBITDA ratio of 0.82 and a ROCE of 13.6%, indicating operational strength.
Mojo Score and Rating Downgrade: The stock’s Mojo Score stands at 43.0 with a ‘Sell’ grade, downgraded from ‘Hold’ on 15 September 2026, reflecting deteriorating fundamentals and market sentiment.
Micro-Cap Volatility: As a micro-cap stock with a market capitalisation of ₹271 crore, Medico Remedies is subject to higher volatility and sensitivity to market fluctuations compared to larger peers.
Conclusion: A Challenging Week for Medico Remedies Ltd
Medico Remedies Ltd’s stock endured a difficult week marked by a steep 25.34% decline, culminating in a lower circuit hit and a new 52-week low. The sharp underperformance relative to the Sensex and sector peers highlights significant investor concerns and technical weakness. While the company’s financial results demonstrate encouraging growth in sales and profits, these fundamentals have yet to translate into positive market sentiment or price recovery.
The pervasive bearish technical indicators and heavy selling pressure suggest that the stock remains under strain in the near term. Investors should remain cautious and monitor upcoming corporate developments and sector trends closely. The micro-cap status adds an additional layer of volatility risk, underscoring the need for careful analysis before considering exposure.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
